A non-invasive QPCR method monitoring DNA based therapy of bladder cancer patients.
Real-time PCR technology is highly advantageous for gene studies based on the genetic nature of the transferred material. Urine and blood samples were collected before and after treatment. Treatment of bladder carcinoma patients with plasmid constructs expressing the diphtheria toxin gene was monitored. Detection range from 5x10(6) copies to <or=10 copies was observed with repeatability and reproducibility. No trace amount of the plasmid was detected in the patient's bloodstream, and a continuous clearance in urine, as well, was observed 72 h post-injection. These results show the possibility to design a follow-up method to monitor quantitatively the amount of the plasmid DNA in bladder cancer patients.
Ayesh
Suhail
S
The Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, and Molecular Genetics Laboratory, Makassed Islamic Charitable Hospital, Jerusalem, Israel. suhail@cc.Is.huji.ac.il
Abu-Lail
Rasha
R
Hochberg
Abraham
A
D004247:DNA / Q000032:analysis* / Q000097:blood / Q000652:urine; D018628:Gene Dosage; D015316:Genetic Therapy; D006801:Humans; D010957:Plasmids / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction / Q000379:methods*; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D004247:DNA